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In this issue of Immunity, Hong et al. (2012) report the first structural analysis of the C-terminal fragment of
an NLR (nucleotide-binding domain [NBD] and leucine-rich repeat [LRR]-containing) protein, NLRX1. This
fragment forms a hexamer and binds RNA.The NLR (nucleotide-binding domain
[NBD] and leucine-rich repeat [LRR]-con-
taining) proteins are a large protein family
that plays important roles in a wide range
of biological processes, a prime function
of which is the detection of pathogen-
associated molecular patterns (PAMPs).
NLRX1 is the first NLR protein shown to
be localized at the mitochondria. It has
been associated with multiple functions,
including negatively impacting antiviral
inflammatory response via the MAVS-
RIG-I sensing pathway (Moore et al.,
2008; Xia et al., 2011) or lipopolisacchar-
ide-elicited response via the TRAF6-IKK
signaling pathway (Allen et al., 2011; Xia
et al., 2011) and positively controlling
NF-kB and JNK signaling pathway to acti-
vate reactive oxygen species (ROS) pro-
duction in response to TNF-a, poly(I:C),
and pathogens (Abdul-Sater et al., 2010;
Tattoli et al., 2008). Gene deletion of
exons 4 and 5 within the Nlrx1 gene re-
sulted in elevated type I interferon (IFN-I)
and IL-6 response to viral infection in cells
and whole animals and in a modest
reduction of basal ROS in innate immune
cells (Allen et al., 2011). A different gene-
targeted strain showed reduced ROS
production to Chlamydia, although the
deleted genetic sequence was not
described (Abdul-Sater et al., 2010). A
third group studied a strain that has a
deletion of the first four exons of Nlrx1
(Rebsamen et al., 2011). These authors
did not detect an effect of this deletion
on either IFN expression or TNF-a amplifi-
cation of NF-kB and JNK signaling. In
addition to possibly mediating different
functions, the precise site of cellular local-
ization varies in different reports. Although
one group has found endogenous NLRX1
localization as a mitochondrial outermembrane (MOM) protein (Moore et al.,
2008), another group has shown its
localization in the mitochondrial matrix
(Arnoult et al., 2009). Different serologic
reagents were used in these localization
studies, which might impact the outcome.
Additionally, one has to entertain the
possibility that these varied localizations
may be relevant to the multiple functions
of NLRX1 reported to date.
Hong et al. (2012) in this issue of
Immunity presents the first crystallo-
graphic analysis of the C-terminal frag-
ment of NLRX1 that includes two a-helical
domains flanking a middle LRR section.
Several important and surprising features
of the NLRX1 are revealed in this study.
A key finding is that the NLRX1 LRR and
its associated helical domains form a
hexameric platform composed of a trimer
of three dimers, through extensive intra-
molecular and intermolecular interactions
(Figure 1). These higher-order oligomers
may promote cooperative association
between NLRX1 and its target proteins,
thereby ensuring stringent regulation of
innate immune responses. Although the
NLR nucleotide-binding domain is typi-
cally considered an oligomerization
motif, an early report that first described
oligomerization of the founding NLR
protein CIITA revealed that both NBD
and LRR domains undergo homotypic
(NBD-NBD, LRR-LRR) and heterotypic
(NBD-LRR) association (Linhoff et al.,
2001). In agreement with this, Hong et al.
(2012) show that LRR-LRR interaction
occurs through the C-terminal a-helical
domain (referred to as LRRCT by these
authors)-mediated intra- and intermolec-
ular interactions at the dimer interface
and the N-terminal a-helical domain
(referred to as LRRNT)-mediated intermo-Immunity 3lecular interactions at the trimer interface.
Whether the NLRX1 NBD promotes
further oligomerization of NLRX1 is
unknown. Interestingly, the NLRX1 NBD
has a classic Walker A motif that binds
ATP but a poor Walker B motif. It is
possible that an uncommon ATP binding
motif endows different oligomerization
function for the NLRX1 NBD.
A second finding in this paper relates
to how NLRs detect PAMPs, a central
unresolved issue in the field. One of the
most studied NLRs is NLRP3, which
mediates inflammasome response to
numerous PAMPs and DAMPs (damage-
associated molecular patterns). An
emerging consensus is that NLRP3 is
unlikely to directly bind to such a wide
variety of molecular structures. Rather, it
might ‘‘sense’’ PAMPs and DAMPs
through indirect detection by an interme-
diate moieties that remains elusive. A
recent large-scale analysis of plant NLRs
has been illuminating regarding the inter-
section of NLRs and PAMPs. This work
shows that only 2 of 30 NLRs directly
interact with PAMPs (pathogen effectors)
(Mukhtar et al., 2011). By contrast, nearly
half of the host cell proteins that interact
with NLRs are direct targets of pathogen
effectors. These findings led to the con-
clusion that a majority of pathogen effec-
tors interact with host proteins that in
turn activate plant NLRs, while a minority
directly associate with NLRs. Support for
the latter is emerging in mammalian cells
although direct binding between NLRs
and their respective ligands have yet to
be demonstrated in a purified recombi-
nant system.
Hong et al. (2012) used a purified re-
combinant C-terminal fragment of
NLRX1 to demonstrate its binding to6, March 23, 2012 ª2012 Elsevier Inc. 311
Figure 1. A Working Model of NLRX1 Function
The C-terminal fragment of NLRX1 is comprised of the LRR flanked by N- and C-terminal a helices to
form a hexamer, with the trimeric leucine-rich repeats resembling a tri-blade boomerang (magenta, green,
and blue as one trimer and pink, lime, and cyan as the other; see insert). The identified RNA binding sites
aremarked in yellow. This oligomerization platformmay promote cooperative association between NLRX1
and its downstream target. In this model, NLRX1 constitutively binds toMAVS to inhibit its function (Moore
et al., 2008; Allen et al., 2011; Xia et al., 2011), while RNA binding to NLRX1 releases MAVS. RNA-bound
NLRX1 then activates ROS. The model proposes a possible NLRX1 translocation fromMOM to the matrix
via an unknown modification or mechanism, which allows interaction with potential downstream target to
activate ROS. The functional connection of NLRX1 and UQCRC2 is proposed and not experimentally
demonstrated.
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DNA. Based on the X-ray crystallographic
analysis, they identified a large contin-
uous positively charged surface patch
that might represent the RNA binding
face. A single-residue mutation within
this patch greatly reduced RNA binding
by purified NLRX1 in a gel-shift assay.
This mutant protein failed to induce ROS
upon stimulation with poly(I:C). However,
further characterization of NLRX1 coloc-
alization with RNAwithin cells is important
for physiological verification, and cocrys-
tallization of NLRX1 with RNA would be
a strong confirmation of this interaction.
Finally, exactly where NLRX1 binds RNA
within the cell is important. As mentioned
earlier, NLRX1 has been localized to the
MOM and mitochondria matrix in sepa-
rate studies. Specifically, NLRX1 interacts312 Immunity 36, March 23, 2012 ª2012 Elsewith a mitochondrial matrix protein,
UQCRC2, which is a component of the
respiratory chain complex III, thus pro-
viding a possible basis for ROS induction
by NLRX1 (Figure 1; Arnoult et al., 2009;
Rebsamen et al., 2011). The current
work used ROS induction upon poly(I:C)
stimulation as a readout. Although it is
conceivable that viral RNA bind to
NLRX1 at the MOM, it is more difficult to
envision how NLRX1 can access viral
RNA from the mitochondria matrix. How-
ever, as revealed by this work, there is
much that we do not understand about
this fascinating protein, and only addi-
tional studies can clarify these issues.
Exactly how RNA binding elicits the
biological function of NLRX1 is unclear.
Does RNA binding to NLRX1 influence
NLRX1-UQCRC2 association to affectvier Inc.ROS production? One report showed
that endogenous NLRX1 constitutively
interacts with MAVS (Moore et al., 2008).
Does RNA induce conformational
changes or oligomerization states of
NLRX1 so that NLRX1 releases MAVS to
allow for RIG-1 signaling? The hexameric
full-length NLRX1 model shows close
proximity of its RNA binding surface with
the modeled NBD. It is conceivable that
RNA binding at LRR and MAVS binding
at NBD are mutually exclusive, thus
providing a mechanism to release the
repression of the RIG-1 pathway upon
RNA exposure to both RIG-1 and
NLRX1. The above working models can
now be tested with the information pro-
vided by Hong et al. (2012).REFERENCES
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